共 60 条
[1]
Abdelsalam A, 2017, EGYPT RHEUMATOL, V39, P109, DOI 10.1016/j.ejr.2016.08.002
[5]
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
[J].
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY,
2017, 76 (03)
:405-417
[6]
Bogliolo L, 2005, J RHEUMATOL, V32, P511